{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T18:22:09Z","timestamp":1787422929219,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"DOI":"10.1007\/s00592-024-02363-5","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T04:02:02Z","timestamp":1725940922000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["\u201cEmerging clinical approaches in diabetic cardiomyopathy: insights from clinical trials and future directions\u201d"],"prefix":"10.1007","volume":"62","author":[{"given":"Murali Krishna","family":"Moka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriram. D.","family":"K","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1565-3824","authenticated-orcid":false,"given":"Melvin","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"2363_CR1","doi-asserted-by":"publisher","first-page":"11056","DOI":"10.3390\/ijerph182111056","volume":"18","author":"S Ueno","year":"2021","unstructured":"Ueno S, Aung MN, Yuasa M et al (2021) Association between Dietary habits and type 2 diabetes Mellitus in Yangon, Myanmar: a case\u2013control study. Int J Environ Res Public Health 18:11056. https:\/\/doi.org\/10.3390\/ijerph182111056","journal-title":"Int J Environ Res Public Health"},{"key":"2363_CR2","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.4103\/ijo.IJO_1627_21","volume":"69","author":"R Pradeepa","year":"2021","unstructured":"Pradeepa R, Mohan V (2021) Epidemiology of type 2 diabetes in India. Indian J Ophthalmol 69:2932. https:\/\/doi.org\/10.4103\/ijo.IJO_1627_21","journal-title":"Indian J Ophthalmol"},{"key":"2363_CR3","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1161\/CIRCRESAHA.115.306884","volume":"118","author":"JA Beckman","year":"2016","unstructured":"Beckman JA, Creager MA (2016) Vascular complications of diabetes. Circ Res 118:1771\u20131785. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306884","journal-title":"Circ Res"},{"key":"2363_CR4","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia G, Hill MA, Sowers JR (2018) Diabetic Cardiomyopathy. Circ Res 122:624\u2013638. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311586","journal-title":"Circ Res"},{"key":"2363_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.695792","author":"T Salvatore","year":"2021","unstructured":"Salvatore T, Pafundi PC, Galiero R et al (2021) The Diabetic Cardiomyopathy: the contributing pathophysiological mechanisms. Front Med. https:\/\/doi.org\/10.3389\/fmed.2021.695792. 8:","journal-title":"Front Med"},{"key":"2363_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.hfc.2019.02.003","volume":"15","author":"S Paolillo","year":"2019","unstructured":"Paolillo S, Marsico F, Prastaro M et al (2019) Diabetic Cardiomyopathy. Heart Fail Clin 15:341\u2013347. https:\/\/doi.org\/10.1016\/j.hfc.2019.02.003","journal-title":"Heart Fail Clin"},{"key":"2363_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12933-017-0506-x","volume":"16","author":"A Lorenzo-Almor\u00f3s","year":"2017","unstructured":"Lorenzo-Almor\u00f3s A, Tu\u00f1\u00f3n J, Orejas M et al (2017) Diagnostic approaches for diabetic cardiomyopathy. Cardiovasc Diabetol 16:28. https:\/\/doi.org\/10.1186\/s12933-017-0506-x","journal-title":"Cardiovasc Diabetol"},{"key":"2363_CR8","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.3390\/biomedicines10102436","volume":"10","author":"C Aloke","year":"2022","unstructured":"Aloke C, Egwu CO, Aja PM et al (2022) Current advances in the management of diabetes Mellitus. Biomedicines 10:2436. https:\/\/doi.org\/10.3390\/biomedicines10102436","journal-title":"Biomedicines"},{"key":"2363_CR9","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00592-021-01705-x","volume":"58","author":"R Marfella","year":"2021","unstructured":"Marfella R, Sardu C, Mansueto G et al (2021) Evidence for human diabetic cardiomyopathy. Acta Diabetol 58:983\u2013988. https:\/\/doi.org\/10.1007\/s00592-021-01705-x","journal-title":"Acta Diabetol"},{"key":"2363_CR10","doi-asserted-by":"publisher","first-page":"154936","DOI":"10.1016\/j.metabol.2021.154936","volume":"127","author":"R Marfella","year":"2022","unstructured":"Marfella R, D\u2019Onofrio N, Trotta MC et al (2022) Sodium\/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts. Metabolism 127:154936. https:\/\/doi.org\/10.1016\/j.metabol.2021.154936","journal-title":"Metabolism"},{"key":"2363_CR11","doi-asserted-by":"publisher","first-page":"106448","DOI":"10.1016\/j.phrs.2022.106448","volume":"184","author":"R Marfella","year":"2022","unstructured":"Marfella R, Scisciola L, D\u2019Onofrio N et al (2022) Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes. Pharmacol Res 184:106448. https:\/\/doi.org\/10.1016\/j.phrs.2022.106448","journal-title":"Pharmacol Res"},{"key":"2363_CR12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12933-022-01573-x","volume":"21","author":"R Marfella","year":"2022","unstructured":"Marfella R, D\u2019Onofrio N, Mansueto G et al (2022) Glycated ACE2 reduces anti-remodeling effects of renin-angiotensin system inhibition in human diabetic hearts. Cardiovasc Diabetol 21:146. https:\/\/doi.org\/10.1186\/s12933-022-01573-x","journal-title":"Cardiovasc Diabetol"},{"key":"2363_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s13300-024-01532-7","volume":"15","author":"J Yin","year":"2024","unstructured":"Yin J, Fu X, Luo Y et al (2024) A narrative review of Diabetic Macroangiopathy: from molecular mechanism to therapeutic approaches. Diabetes Ther 15:585\u2013609. https:\/\/doi.org\/10.1007\/s13300-024-01532-7","journal-title":"Diabetes Ther"},{"key":"2363_CR14","doi-asserted-by":"publisher","unstructured":"Krishna Mohan GV, Tirumandyam G, Vemulapalli HS et al (2023) Mesenchymal stem cell therapy for a Better Prognosis of Heart Failure: a systematic review and Meta-analysis of Randomized controlled trials. https:\/\/doi.org\/10.7759\/cureus.43037. Cureus","DOI":"10.7759\/cureus.43037"},{"key":"2363_CR15","doi-asserted-by":"publisher","first-page":"e0234260","DOI":"10.1371\/journal.pone.0234260","volume":"15","author":"C Meindl","year":"2020","unstructured":"Meindl C, Hochadel M, Frankenstein L et al (2020) The role of diabetes in cardiomyopathies of different etiologies\u2014characteristics and 1-year follow-up results of the EVITA-HF registry. PLoS ONE 15:e0234260. https:\/\/doi.org\/10.1371\/journal.pone.0234260","journal-title":"PLoS ONE"},{"key":"2363_CR16","doi-asserted-by":"publisher","unstructured":"Abouzid MR, Umer AM, Jha SK et al (2024) Stem cell therapy for myocardial infarction and heart failure: a comprehensive systematic review and critical analysis. https:\/\/doi.org\/10.7759\/cureus.59474. Cureus","DOI":"10.7759\/cureus.59474"},{"key":"2363_CR17","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.3390\/ijms21176043","volume":"21","author":"FF Jubaidi","year":"2020","unstructured":"Jubaidi FF, Zainalabidin S, Mariappan V, Budin SB (2020) Mitochondrial dysfunction in Diabetic Cardiomyopathy: the possible therapeutic roles of phenolic acids. Int J Mol Sci 21:6043. https:\/\/doi.org\/10.3390\/ijms21176043","journal-title":"Int J Mol Sci"},{"key":"2363_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/jcdd10070287","volume":"10","author":"R Spoladore","year":"2023","unstructured":"Spoladore R, Pinto G, Daus F et al (2023) Metabolic approaches for the Treatment of Dilated Cardiomyopathy. J Cardiovasc Dev Dis 10:287. https:\/\/doi.org\/10.3390\/jcdd10070287","journal-title":"J Cardiovasc Dev Dis"},{"key":"2363_CR19","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.2337\/db21-0270","volume":"70","author":"S Thirunavukarasu","year":"2021","unstructured":"Thirunavukarasu S, Jex N, Chowdhary A et al (2021) Empagliflozin Treatment is Associated with improvements in Cardiac energetics and function and reductions in Myocardial Cellular volume in patients with type 2 diabetes. Diabetes 70:2810\u20132822. https:\/\/doi.org\/10.2337\/db21-0270","journal-title":"Diabetes"},{"key":"2363_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045894019865158","volume":"9","author":"B Liu","year":"2019","unstructured":"Liu B, Wu W, Zeng Q et al (2019) Left ventricular peak early diastolic strain rate detected by two-dimensional speckle tracking echocardiography and disease severity in pre\u2010capillary pulmonary hypertension. Pulm Circ 9:1\u20139. https:\/\/doi.org\/10.1177\/2045894019865158","journal-title":"Pulm Circ"},{"key":"2363_CR21","doi-asserted-by":"publisher","unstructured":"Kerr M, Miller JJ, Thapa D et al (2020) Rescue of myocardial energetic dysfunction in diabetes through the correction of mitochondrial hyperacetylation by honokiol. JCI Insight 5. https:\/\/doi.org\/10.1172\/jci.insight.140326","DOI":"10.1172\/jci.insight.140326"},{"key":"2363_CR22","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s10637-010-9627-8","volume":"30","author":"B Toffoli","year":"2012","unstructured":"Toffoli B, Bernardi S, Candido R et al (2012) TRAIL shows potential cardioprotective activity. Invest New Drugs 30:1257\u20131260. https:\/\/doi.org\/10.1007\/s10637-010-9627-8","journal-title":"Invest New Drugs"},{"key":"2363_CR23","doi-asserted-by":"publisher","unstructured":"Toedebusch R, Belenchia A, Pulakat L (2018) Diabetic Cardiomyopathy: impact of Biological Sex on Disease Development and Molecular signatures. Front Physiol 9. https:\/\/doi.org\/10.3389\/fphys.2018.00453","DOI":"10.3389\/fphys.2018.00453"},{"key":"2363_CR24","doi-asserted-by":"publisher","unstructured":"Zhao X, Liu S, Wang X et al (2022) Diabetic cardiomyopathy: clinical phenotype and practice. Front Endocrinol (Lausanne) 13. https:\/\/doi.org\/10.3389\/fendo.2022.1032268","DOI":"10.3389\/fendo.2022.1032268"},{"key":"2363_CR25","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1002\/ehf2.13412","volume":"8","author":"TJ Pfeffer","year":"2021","unstructured":"Pfeffer TJ, List M, M\u00fcller JH et al (2021) Perhexiline treatment improves toxic effects of \u03b2-adrenergic receptor stimulation in experimental peripartum cardiomyopathy. ESC Hear Fail 8:3375\u20133381. https:\/\/doi.org\/10.1002\/ehf2.13412","journal-title":"ESC Hear Fail"},{"key":"2363_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jchf.2014.09.009","volume":"3","author":"RM Beadle","year":"2015","unstructured":"Beadle RM, Williams LK, Kuehl M et al (2015) Improvement in Cardiac Energetics by Perhexiline in Heart failure due to dilated cardiomyopathy. JACC Hear Fail 3:202\u2013211. https:\/\/doi.org\/10.1016\/j.jchf.2014.09.009","journal-title":"JACC Hear Fail"},{"key":"2363_CR27","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/jcph.1934","volume":"61","author":"MG Midei","year":"2021","unstructured":"Midei MG, Darpo B, Ayers G et al (2021) Electrophysiological and ECG effects of Perhexiline, a mixed Cardiac Ion Channel inhibitor, evaluated in nonclinical assays and in healthy subjects. J Clin Pharmacol 61:1606\u20131617. https:\/\/doi.org\/10.1002\/jcph.1934","journal-title":"J Clin Pharmacol"},{"key":"2363_CR28","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","volume":"122","author":"K Abozguia","year":"2010","unstructured":"Abozguia K, Elliott P, McKenna W et al (2010) Metabolic Modulator Perhexiline Corrects Energy Deficiency and improves Exercise Capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122:1562\u20131569. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.934059","journal-title":"Circulation"},{"key":"2363_CR29","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1161\/CIRCULATIONAHA.105.551457","volume":"112","author":"L Lee","year":"2005","unstructured":"Lee L, Campbell R, Scheuermann-Freestone M et al (2005) Metabolic modulation with Perhexiline in Chronic Heart failure. Circulation 112:3280\u20133288. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.551457","journal-title":"Circulation"},{"key":"2363_CR30","doi-asserted-by":"publisher","first-page":"e0265642","DOI":"10.1371\/journal.pone.0265642","volume":"17","author":"H Hu","year":"2022","unstructured":"Hu H, Zhao X, Jin X et al (2022) Efficacy and safety of eplerenone treatment for patients with diabetic nephropathy: a meta-analysis. PLoS ONE 17:e0265642. https:\/\/doi.org\/10.1371\/journal.pone.0265642","journal-title":"PLoS ONE"},{"key":"2363_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1475-2840-12-139","volume":"12","author":"M Leung","year":"2013","unstructured":"Leung M, Wong VW, Heritier S et al (2013) Rationale and design of a randomized trial on the impact of aldosterone antagonism on cardiac structure and function in diabetic cardiomyopathy. Cardiovasc Diabetol 12:139. https:\/\/doi.org\/10.1186\/1475-2840-12-139","journal-title":"Cardiovasc Diabetol"},{"key":"2363_CR32","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1177\/1470320313515037","volume":"16","author":"A Zakrzeska","year":"2015","unstructured":"Zakrzeska A, Gromotowicz-Pop\u0142awska A, Szemraj J et al (2015) Eplerenone reduces arterial thrombosis in diabetic rats. J Renin-Angiotensin-Aldosterone Syst 16:1085\u20131094. https:\/\/doi.org\/10.1177\/1470320313515037","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"key":"2363_CR33","doi-asserted-by":"publisher","unstructured":"De Brouwer R, Te Rijdt WP, Hoorntje ET et al (2022) The effect of eplerenone on the disease onset and progression of phospholamban cardiomyopathy in presymptomatic mutation carriers: results of the i-PHORECAST trial. Eur Heart J 43. https:\/\/doi.org\/10.1093\/eurheartj\/ehac544.2663","DOI":"10.1093\/eurheartj\/ehac544.2663"},{"key":"2363_CR34","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/1475-2840-12-172","volume":"12","author":"E Ram\u00edrez","year":"2013","unstructured":"Ram\u00edrez E, Klett-Mingo M, Ares-Carrasco S et al (2013) Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes. Cardiovasc Diabetol 12:172. https:\/\/doi.org\/10.1186\/1475-2840-12-172","journal-title":"Cardiovasc Diabetol"},{"key":"2363_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11010-018-3276-1","volume":"446","author":"UB Mahajan","year":"2018","unstructured":"Mahajan UB, Patil PD, Chandrayan G et al (2018) Eplerenone pretreatment protects the myocardium against ischaemia\/reperfusion injury through the phosphatidylinositol 3-kinase\/Akt-dependent pathway in diabetic rats. Mol Cell Biochem 446:91\u2013103. https:\/\/doi.org\/10.1007\/s11010-018-3276-1","journal-title":"Mol Cell Biochem"},{"key":"2363_CR36","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/diagnostics14050463","volume":"14","author":"D Bedo","year":"2024","unstructured":"Bedo D, Beaudrey T, Florens N (2024) Unraveling chronic Cardiovascular and kidney disorder through the Butterfly Effect. Diagnostics 14:463. https:\/\/doi.org\/10.3390\/diagnostics14050463","journal-title":"Diagnostics"},{"key":"2363_CR37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.rceng.2016.07.003","volume":"217","author":"T Lozano","year":"2017","unstructured":"Lozano T, Ena J (2017) Cardiovascular autonomic neuropathy in patients with diabetes mellitus. Rev Cl\u00ednica Espa\u00f1ola (English Ed 217:46\u201354. https:\/\/doi.org\/10.1016\/j.rceng.2016.07.003","journal-title":"Rev Cl\u00ednica Espa\u00f1ola (English Ed"},{"key":"2363_CR38","doi-asserted-by":"publisher","first-page":"e871","DOI":"10.1097\/MJT.0000000000000180","volume":"23","author":"CA D\u00e9zsi","year":"2016","unstructured":"D\u00e9zsi CA (2016) Trimetazidine in practice. Am J Ther 23:e871\u2013e879. https:\/\/doi.org\/10.1097\/MJT.0000000000000180","journal-title":"Am J Ther"},{"key":"2363_CR39","doi-asserted-by":"publisher","unstructured":"Shu H, Peng Y, Hang W et al (2021) Trimetazidine in Heart failure. https:\/\/doi.org\/10.3389\/fphar.2020.569132. Front Pharmacol 11:","DOI":"10.3389\/fphar.2020.569132"},{"key":"2363_CR40","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3390\/ph17040464","volume":"17","author":"Y Kamisah","year":"2024","unstructured":"Kamisah Y, Che Hassan HH (2024) Role of Trimetazidine in ameliorating endothelial dysfunction: a review. Pharmaceuticals 17:464. https:\/\/doi.org\/10.3390\/ph17040464","journal-title":"Pharmaceuticals"},{"key":"2363_CR41","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s10557-022-07340-0","volume":"37","author":"NM El-khodary","year":"2023","unstructured":"El-khodary NM, Ghoneim AI, El-tayaar AA, El-touny EM (2023) The impact of Trimetazidine on Cardiac Fibrosis, inflammation, and function in ischemic cardiomyopathy patients. Cardiovasc Drugs Ther 37:955\u2013964. https:\/\/doi.org\/10.1007\/s10557-022-07340-0","journal-title":"Cardiovasc Drugs Ther"},{"key":"2363_CR42","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10557-021-07259-y","volume":"37","author":"G Qian","year":"2023","unstructured":"Qian G, A X, Jiang X et al (2023) Early trimetazidine therapy in patients undergoing primary percutaneous coronary intervention for ST Segment Elevation Myocardial Infarction reduces myocardial infarction size. Cardiovasc Drugs Ther 37:497\u2013506. https:\/\/doi.org\/10.1007\/s10557-021-07259-y","journal-title":"Cardiovasc Drugs Ther"},{"key":"2363_CR43","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s12872-021-02287-w","volume":"21","author":"Z-L Dai","year":"2021","unstructured":"Dai Z-L, Song Y-F, Tian Y et al (2021) Trimetazidine offers myocardial protection in elderly coronary artery disease patients undergoing non-cardiac surgery: a randomized, double-blind, placebo-controlled trial. BMC Cardiovasc Disord 21:473. https:\/\/doi.org\/10.1186\/s12872-021-02287-w","journal-title":"BMC Cardiovasc Disord"},{"key":"2363_CR44","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamacardio.2018.4847","volume":"4","author":"CJ Coats","year":"2019","unstructured":"Coats CJ, Pavlou M, Watkinson OT et al (2019) Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in patients with nonobstructive hypertrophic cardiomyopathy. JAMA Cardiol 4:230. https:\/\/doi.org\/10.1001\/jamacardio.2018.4847","journal-title":"JAMA Cardiol"},{"key":"2363_CR45","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12872-020-01557-3","volume":"20","author":"L Wu","year":"2020","unstructured":"Wu L, Luan Y, Li Y et al (2020) Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial. BMC Cardiovasc Disord 20:273. https:\/\/doi.org\/10.1186\/s12872-020-01557-3","journal-title":"BMC Cardiovasc Disord"},{"key":"2363_CR46","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.3390\/jcm11061470","volume":"11","author":"DM Keller","year":"2022","unstructured":"Keller DM, Ahmed N, Tariq H et al (2022) SGLT2 inhibitors in type 2 diabetes Mellitus and Heart Failure\u2014A Concise Review. J Clin Med 11:1470. https:\/\/doi.org\/10.3390\/jcm11061470","journal-title":"J Clin Med"},{"key":"2363_CR47","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/IJNRD.S234282","volume":"15","author":"K Nashar","year":"2022","unstructured":"Nashar K, Khalil P (2022) Clinical evaluation of Dapagliflozin in the management of CKD: focus on patient selection and clinical perspectives. Int J Nephrol Renovasc Dis Volume 15:289\u2013308. https:\/\/doi.org\/10.2147\/IJNRD.S234282","journal-title":"Int J Nephrol Renovasc Dis Volume"},{"key":"2363_CR48","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1093\/eurheartj\/ehaa419","volume":"41","author":"AJM Brown","year":"2020","unstructured":"Brown AJM, Gandy S, McCrimmon R et al (2020) A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. Eur Heart J 41:3421\u20133432. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa419","journal-title":"Eur Heart J"},{"key":"2363_CR49","doi-asserted-by":"publisher","first-page":"116650","DOI":"10.1016\/j.biopha.2024.116650","volume":"175","author":"R Madonna","year":"2024","unstructured":"Madonna R, Biondi F, Alberti M et al (2024) Cardiovascular outcomes and molecular targets for the cardiac effects of sodium-glucose cotransporter 2 inhibitors: a systematic review. Biomed Pharmacother 175:116650. https:\/\/doi.org\/10.1016\/j.biopha.2024.116650","journal-title":"Biomed Pharmacother"},{"key":"2363_CR50","doi-asserted-by":"publisher","unstructured":"Pofi R, Giannetta E, Feola T et al (2022) Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. Sci Transl Med 14. https:\/\/doi.org\/10.1126\/scitranslmed.abl8503","DOI":"10.1126\/scitranslmed.abl8503"},{"key":"2363_CR51","doi-asserted-by":"publisher","unstructured":"Gianfrilli D, Pofi R, Feola T et al (2017) The woman\u2019s heart: insights into new potential targeted therapy. Curr Med Chem 24. https:\/\/doi.org\/10.2174\/0929867324666161118121647","DOI":"10.2174\/0929867324666161118121647"},{"key":"2363_CR52","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/endocrines1020009","volume":"1","author":"F Barbagallo","year":"2020","unstructured":"Barbagallo F, Campolo F, Franceschini E et al (2020) PDE5 inhibitors in type 2 Diabetes Cardiovascular complications. Endocrines 1:90\u2013101. https:\/\/doi.org\/10.3390\/endocrines1020009","journal-title":"Endocrines"},{"key":"2363_CR53","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1517\/14728222.2015.1066337","volume":"19","author":"E Mandosi","year":"2015","unstructured":"Mandosi E, Giannetta E, Filardi T et al (2015) Endothelial dysfunction markers as a therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes. Expert Opin Ther Targets 19:1617\u20131622. https:\/\/doi.org\/10.1517\/14728222.2015.1066337","journal-title":"Expert Opin Ther Targets"},{"key":"2363_CR54","doi-asserted-by":"publisher","first-page":"166369","DOI":"10.1016\/j.bbadis.2022.166369","volume":"1868","author":"J Qian","year":"2022","unstructured":"Qian J, Zhuang F, Chen Y et al (2022) Myeloid differential protein-2 inhibition improves diabetic cardiomyopathy via p38MAPK inhibition and AMPK pathway activation. Biochim Biophys Acta - Mol Basis Dis 1868:166369. https:\/\/doi.org\/10.1016\/j.bbadis.2022.166369","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"key":"2363_CR55","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-023-01811-w","volume":"22","author":"K Gopal","year":"2023","unstructured":"Gopal K, Karwi QG, Tabatabaei Dakhili SA et al (2023) Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation. Cardiovasc Diabetol 22:73. https:\/\/doi.org\/10.1186\/s12933-023-01811-w","journal-title":"Cardiovasc Diabetol"},{"key":"2363_CR56","doi-asserted-by":"publisher","first-page":"102328","DOI":"10.1016\/j.dsx.2021.102328","volume":"15","author":"J Gaztanaga","year":"2021","unstructured":"Gaztanaga J, Ramasamy R, Schmidt AM et al (2021) A pilot open-label study of aldose reductase inhibition with AT-001 (caficrestat) in patients hospitalized for COVID-19 infection: results from a registry-based matched-control analysis. Diabetes Metab Syndr Clin Res Rev 15:102328. https:\/\/doi.org\/10.1016\/j.dsx.2021.102328","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"2363_CR57","doi-asserted-by":"publisher","unstructured":"KARWI QG, GOPAL K, AMIRHOSSEIN TABATABAEI DAKHILI S et al (2022) 207-LB: Aldose Reductase inhibition by AT-001 limits diastolic dysfunction and adverse remodelling in Diabetic Cardiomyopathy. Diabetes 71. https:\/\/doi.org\/10.2337\/db22-207-LB","DOI":"10.2337\/db22-207-LB"},{"key":"2363_CR58","doi-asserted-by":"publisher","first-page":"154986","DOI":"10.1016\/j.metabol.2021.154986","volume":"128","author":"K Gopal","year":"2022","unstructured":"Gopal K, Karwi QG, Tabatabaei-Dakhili SA et al (2022) Aldose reductase inhibition by AT-001 prevents Diabetic Cardiomyopathy Via reducing myocardial fatty acid Oxidation Rates. Metabolism 128:154986. https:\/\/doi.org\/10.1016\/j.metabol.2021.154986","journal-title":"Metabolism"},{"key":"2363_CR59","doi-asserted-by":"publisher","unstructured":"PERFETTI R, YEPURI G, QUADRI NA et al (2020) 1080-P: addressing the Safety challenges of Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy, a potent and selective next generation aldose reductase inhibitor. https:\/\/doi.org\/10.2337\/db20-1080-P. Diabetes 69:","DOI":"10.2337\/db20-1080-P"},{"key":"2363_CR60","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ahj.2022.11.003","volume":"256","author":"JL Januzzi","year":"2023","unstructured":"Januzzi JL, Butler J, Del Prato S et al (2023) Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart failure trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy. Am Heart J 256:25\u201336. https:\/\/doi.org\/10.1016\/j.ahj.2022.11.003","journal-title":"Am Heart J"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-024-02363-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-024-02363-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-024-02363-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T04:48:48Z","timestamp":1737953328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-024-02363-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["2363"],"URL":"https:\/\/doi.org\/10.1007\/s00592-024-02363-5","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"19 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No informed consent was required for the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}